MD1003-AMN MD1003 in Adrenomyeloneuropathy

NCT02961803 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Adrenomyeloneuropathy
Adrenoleukodystrophy
AMN

Interventions

DRUG: MD1003 100 mg capsule
DRUG: Placebo

Sponsor

MedDay Pharmaceuticals SA